Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHRONOS-4
2015-001088-38Phase 3Terminated
- Sponsor
- Bayer
- Start
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of copanlisib in indolent lymphoma and follicular lymphoma (FL) (2 arms), sponsored by Bayer. Primary endpoint: Progression-free survival. Started Sep 2015; status: terminated.
02
Drugs
copanlisib
03
Conditions
indolent lymphomafollicular lymphoma (FL)
Beyond the preview
Go deeper on 2015-001088-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001088-38.